Prognostic factors in carcinomas of unknown primary site

被引:0
|
作者
Seve, P. [2 ,3 ]
Culine, S. [1 ]
机构
[1] CHU Henri Mondor, Med Oncol Serv, F-94010 Creteil, France
[2] Hosp Civils Lyon, Serv Med Interne, F-69288 Lyon 02, France
[3] Univ Lyon 1, Fac Med Lyon Sud, F-69622 Villeurbanne, France
关键词
Carcinoma of unknown primary (CUP); Prognostic factors;
D O I
10.1007/s10269-008-0970-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Carcinomas of unknown primary (CUP) site are a heterogeneous group of tumours with widely variable natural histories and poor survival rates. In a minority of patients, the clinical presentation similar to that of known primar cancers at an equivalent stage has resulted in the identification of subsets of patients with favourable clinical and pathological features. Their recognition is of major importance since specific management may prolong survival. For the vast majority of patients with CUP however, the identification of reliable prognostic indicators has proven challenging. A number of studies with multivariate analyses identified poor performance status, liver metastases, abnormal serum lacticodehydrogenase levels, and low serum albumin as main recurrent adverse prognostic factors. Adequate knowledge of prognostic factors may help oncologists in refining the daily management of patients, assessing the results and designing clinical research studies.
引用
收藏
页码:703 / 706
页数:4
相关论文
共 50 条
  • [31] Class III β-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site
    Pascal Sève
    Tony Reiman
    Raymond Lai
    John Hanson
    Cheryl Santos
    Lorelei Johnson
    Laith Dabbagh
    Michael Sawyer
    Charles Dumontet
    John R. Mackey
    Cancer Chemotherapy and Pharmacology, 2007, 60
  • [32] Class III β-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site
    Seve, Pascal
    Reiman, Tony
    Lai, Raymond
    Hanson, John
    Santos, Cheryl
    Johnson, Lorelei
    Dabbagh, Laith
    Sawyer, Michael
    Dumontet, Charles
    Mackey, John R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (01) : 27 - 34
  • [33] Chemotherapy in carcinomas of unknown primary site: A high-dose intensity policy
    Culine, S
    Fabbro, M
    Ychou, M
    Romieu, G
    Cupissol, D
    Pujol, H
    ANNALS OF ONCOLOGY, 1999, 10 (05) : 569 - 575
  • [34] METASTATIC ADENOCARCINOMAS OF UNKNOWN PRIMARY SITE - PROGNOSTIC VARIABLES AND TREATMENT RESULTS
    KAMBHU, SA
    KELSEN, DP
    FIORE, J
    NIEDZWIECKI, D
    CHAPMAN, D
    VINCIGUERRA, V
    ROSENBLUTH, R
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1990, 13 (01): : 55 - 60
  • [35] Prognostic impact of genetic mutations in unfavorable cancer of unknown primary site
    Tang, Chengyu
    Lu, Hsueh-Ju
    Liu, Hsuan
    Huang, Chi-Ying
    Chang, Peter Mu-Hsin
    ANNALS OF ONCOLOGY, 2023, 34 : S1419 - S1419
  • [36] EVALUATION OF THE PROGNOSTIC BENEFIT OF POSTULATING PRIMARY SITE IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY (CUP)
    Das, J.
    Gilani, S. N.
    ANNALS OF ONCOLOGY, 2014, 25
  • [37] Treatment for Patients With Unknown Primary Carcinoma and Unfavorable Prognostic Factors
    Greco, F. Anthony
    Pavlidis, Nicholas
    SEMINARS IN ONCOLOGY, 2009, 36 (01) : 65 - 74
  • [38] Treatment for Patients With Unknown Primary Cancer and Favorable Prognostic Factors
    Hainsworth, John D.
    Fizazi, Karim
    SEMINARS IN ONCOLOGY, 2009, 36 (01) : 44 - 51
  • [39] Assessment of Prognostic Factors, Clinical Features Including the Microbiome, and Treatment Outcomes in Patients with Cancer of Unknown Primary Site
    Dorobisz, Karolina
    Dorobisz, Tadeusz
    Pazdro-Zastawny, Katarzyna
    CANCERS, 2024, 16 (19)
  • [40] PRIMARY SITE UNKNOWN
    不详
    RECENT RESULTS IN CANCER RESEARCH, 1983, 87 : 68 - 70